Inhibitors of CYP3A4, such as
ketoconazole, are predicted to decrease
toremifene metabolism, which may lead to
toxicity (e.g. hot flushes, uterine bleeding,
fatigue, nausea, dizziness).
These warnings are based on indirect evidence and therefore their
clinical importance awaits confirmation.